NeurAegis
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4255 Campus Dr Ste 100, Irvine, Californ...Phone Number
(650) 269-3528Website
www.neuraegis.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About NeurAegis
NeurAegis Inc. is a neuropharmaceutical company focused on developing innovative treatments for neurological disorders, particularly traumatic brain injury (TBI) and epilepsy. The company is pioneering first-in-class protease inhibitors aimed at addressing the urgent medical need for TBI therapies, as there are currently no FDA approved treatments available. With a significant market potential, NeurAegis has received funding from the Department of Defense to advance its concussion therapy. The company is led by an experienced team and holds strong intellectual property in the field.Explore more
NeurAegis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NeurAegis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NeurAegis launches new products
NeurAegis, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NeurAegis recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at NeurAegis
Funding: Get notified immidiatlly once NeurAegis has new funding data
Check if NeurAegis has recently received funding, and reach out quickly before it becomes old news!
Click to see if NeurAegis had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if NeurAegis is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to NeurAegis
Compare insights from companies similar to NeurAegis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
Company Profile Activity
Activity Insights
NeurAegis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NeurAegis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NeurAegis.
NeurAegis Tech Stack
A closer look at the technologies used by NeurAegis
See more technologies
NeurAegis News & Media
NeurAegis Announces Formation of Scientific-Medical Advisory Board
SOUTHBOROUGH, Mass., Dec. 10, 2020 /PRNewswire/ -- NeurAegis, Inc., a neuropharmaceutical company developing breakthrough treatments for neurological disorders, today announced the inaugural members of its Scientific-Medical Advisory Board who will help advance the Company's preclinical...NeurAegis Announces Publication of Preclinical Animal Data Supporting Calpain-2 as a Promising Therapeutic Target for Concussion
SOUTHBOROUGH, Mass., July 1, 2020 /PRNewswire/ -- NeurAegis, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders, today announced the publication of a paper titled "Calpain-2 as a therapeutic target in repeated...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding NeurAegis
Sign Up For FreeTo access detailed company insights
NeurAegis Inc. is a neuropharmaceutical company focused on developing innovative treatments for neurological disorders, particularly traumatic brain injury (TBI) and epilepsy. The company is pioneering first-in-class protease inhibitors aimed at addressing the urgent medical need for TBI therapies, as there are currently no FDA approved treatments... Read More
